CorporatePartneringR&D Collaboration
Almirall's DHODH inhibitor recognized in the Windhover top 10 partnering list in the immunology category
-
Almirall’s discovery LAS186323, a DHODH inhibitor for the treatment of rheumatoid arthritis and multiple sclerosis, to be presented on 18 November in Boston
Barcelona, 13 November 2009.- Almirall receives recognition from Windhover, a company that forms part of the Elsevier Business Intelligence group, in its immunology category for a DHODH inhibitor, LAS186323, a compound from Almirall’s discovery indicated for the treatment of rheumatoid arthritis and multiple sclerosis. The Windhovergroup classifies the “Top 10 most interesting projects available for partnering” into various categories such as cardiovascular/metabolism, oncology, neuroscience and inflammatory/autoimmune.
“Selected projects have met rigorous criteria including unmet medical need, market potential, diversity of indications, strong science, mulit-level partnering opportunities, potential for new opportunities beyond initial indications and corporate stability” said Roger Longman, Managing Director, Pharma, of Elsevier Business Intelligence.
“In Almirall we maintain our commitment to innovative medicines that provide an opportunity for patients as well as progress in pharmaceutical research. We are proud to be included in this list, which values the potential of compounds in our research pipeline as well as Almirall’s capacities in business development”, states Per Andersson, Chief Executive for R&D in Almirall.
Almirall will be presenting information about LAS186323, which is in phase I, on 18 November 2009 during the Windhover’s Therapeutic Area Partnershipsconference to be held in Boston.
About Almirall
Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.
Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.
More information:
Ketchum SEIS
Sonia San Segundo / Patricia Mansilla
91 788 32 00
Press release